基于年龄、中性粒细胞绝对计数和淋巴细胞绝对计数的全球适用「三A」原发性血小板增多症风险模型
该研究在598例原发性血小板增多症患者中评估中性粒细胞、淋巴细胞和单核细胞绝对计数的独立预后价值,建立基于年龄、中性粒细胞绝对计数和淋巴细胞绝对计数的四层AAA风险模型,其预后区分优于IPSET,并在485例外部队列中验证。
要点
- 年龄>70岁HR 16.5(95%CI 9.9-27.4),年龄50-70岁HR 3.7(95%CI 2.3-6.0)。
- 中性粒细胞绝对计数≥8×10⁹/L的HR 2.4(95%CI 1.7-3.3),淋巴细胞绝对计数<1.7×10⁹/L的HR 1.9(95%CI 1.4-2.6)。
- AAA模型高危及中危2组中位生存分别为8年和13.5年,优于IPSET。
核心结论
- 研究提出一个简单且全球适用的原发性血小板增多症生存模型,可作为进一步分子细化的平台。
- 研究提示免疫相关生物标志物在骨髓增殖性肿瘤中可能具有预后工具作用。
研究设计与样本
- 回顾性纳入Mayo Clinic数据库598例原发性血小板增多症患者,中位年龄59岁,女性62%。
- 基因突变分布为JAK2 59%、CALR 27%、三阴性11%、MPL 3%。
- IPSET风险高危21%、中危42%、低危37%;7%(37/515)核型异常,10%(21/205)不良突变(SF3B1/SRSF2/U2AF1/TP53)。
- 中位随访8.4年,记录163例(27%)死亡、71例(12%)纤维化转化、20例(3%)白血病转化。
- 外部验证队列为University of Florence的原发性血小板增多症队列(N=485)。
主要发现
- 多变量分析显示年龄>70岁HR 16.5(95%CI 9.9-27.4),年龄50-70岁HR 3.7(95%CI 2.3-6.0)。
- 中性粒细胞绝对计数≥8×10⁹/L的HR 2.4(95%CI 1.7-3.3),淋巴细胞绝对计数<1.7×10⁹/L的HR 1.9(95%CI 1.4-2.6)。
- 基于HR的评分分别为4、2、1、1分,形成四层AAA模型:高危(5-6分)中位生存8年,HR 30.1(95%CI 17.6-54)。
- 中危2(4分)中位生存13.5年,HR 12.7(95%CI 7.1-23.0);中危1(2-3分)中位生存20.7年,HR 3.8(95%CI 2.3-6.4);低危(0-1分)中位生存47年。
- AAA模型AIC 621优于IPSET的AIC 647,并在外部队列中验证;AAA变量均不能预测无白血病生存,淋巴细胞绝对计数<1.7×10⁹/L与较差的无骨髓纤维化生存相关(p=.01)。
关键数值与推荐
- 年龄>70岁评4分,年龄50-70岁评2分,中性粒细胞绝对计数≥8×10⁹/L评1分,淋巴细胞绝对计数<1.7×10⁹/L评1分。
- 高危5-6分,中危2为4分,中危1为2-3分,低危为0-1分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We examined the individual prognostic contribution of absolute neutrophil (ANC), lymphocyte (ALC), and monocyte (AMC) counts, on overall (OS), leukemia-free (LFS), and myelofibrosis-free (MFFS) survival in essential thrombocythemia (ET). Informative cases (N = 598; median age 59 years; females 62%) were retrospectively accrued from a Mayo Clinic database: JAK2 59%, CALR 27%, triple-negative 11%, and MPL 3%; international prognostic scoring system for ET (IPSET) risk high 21%, intermediate 42%, and low 37%; 7% (37/515) had abnormal karyotype and 10% (21/205) adverse mutations (SF3B1/SRSF2/U2AF1/TP53). At median 8.4 years, 163 (27%) deaths, 71 (12%) fibrotic, and 20 (3%) leukemic transformations were recorded. Multivariable analysis resulted in HR (95% CI) of 16.5 (9.9-27.4) for age > 70 years, 3.7 (2.3-6.0) for age 50-70 years, 2.4 (1.7-3.3) for ANC ≥8 × 109 /L, and 1.9 (1.4-2.6) for ALC <1.7 × 109 /L. The corresponding HR-based scores were 4, 2, 1, and 1, resulting in an new 4-tiered AgeAncAlc (AAA; triple A) risk model: high (5-6 points; median survival 8 years; HR 30.1, 95% CI 17.6-54), intermediate-2 (4 points; median 13.5 years; HR 12.7, 95% CI 7.1-23.0), intermediate-1 (2-3 points; median 20.7 years; HR 3.8, 95% CI 2.3-6.4) and low (0-1 points; median 47 years). The AAA model (Akaike Information Criterion [AIC] 621) performed better than IPSET (AIC 647) and was subsequently validated by an external University of Florence ET cohort (N = 485). None of the AAA variables predicted LFS while ALC <1.7 × 109 /L was associated with inferior MFFS (p = .01). Adverse mutations (p < .01) and karyotype (p < .01) displayed additional prognostic value without disqualifying the prognostic integrity of the AAA model. This study proposes a simple and globally applicable survival model for ET, which can be used as a platform for further molecular refinement. This study also suggests a potential role for immune-related biomarkers, as a prognostic tool in myeloproliferative neoplasms.
引用
- Tefferi A, Loscocco GG, Farrukh F, et al. A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol. 2023. PMID: 37665758. doi:10.1002/ajh.27079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。